NCT04138394 (VICToRY) is a Phase 3 clinical trial of Ascorbic Acid in Shock, sponsored by Clinical Evaluation Research Unit at Kingston General Hospital.

Who is sponsoring NCT04138394?

NCT04138394 is sponsored by Clinical Evaluation Research Unit at Kingston General Hospital.

What drugs are being tested in NCT04138394?

Interventions in NCT04138394: Ascorbic Acid, placebo.

What condition does NCT04138394 study?

NCT04138394 studies Shock, Thermal Burn.

Is NCT04138394 still recruiting?

NCT04138394 is currently suspended. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT04138394: VICToRY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VItamin C in Thermal injuRY: The VICToRY Trial

Suspended Phase 3 Last updated 6 April 2026

What this trial tests

Phase 3 trial testing Ascorbic Acid in Shock in 666 participants. Suspended.

Timeline

24 July 2020

Primary endpoint
18 December 2025

31 March 2026

Quick facts

Lead sponsor	Clinical Evaluation Research Unit at Kingston General Hospital
Phase	Phase 3
Status	Suspended
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	quadruple
Primary purpose	treatment
Enrollment	666
Start date	24 July 2020
Primary completion	18 December 2025
Estimated completion	31 March 2026
Sites	33 locations across Costa Rica, Belgium, United Kingdom, Germany, Paraguay, Mexico, Canada, Thailand

Drugs / interventions tested

Ascorbic Acid (ASCORBIC ACID) — full drug profile →
placebo

Conditions studied

Shock — all drugs for Shock →
Thermal Burn — all drugs for Thermal Burn →

Sponsor

Clinical Evaluation Research Unit at Kingston General Hospital

Who can join

18 and older, any sex, with Shock or Thermal Burn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin C, while the other half of patients will receive placebo.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C.
Vollbracht C, Kraft K. · · 2022 · cited 97× · PMID 35571085 · DOI 10.3389/fphar.2022.899198
Nutritional and metabolic modulation of inflammation in critically ill patients: a narrative review of rationale, evidence and grey areas.
Rousseau AF, Martindale R. · · 2024 · cited 18× · PMID 39088114 · DOI 10.1186/s13613-024-01350-x
Intravenous vitamin C monotherapy in critically ill patients: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
Lee ZY, Ortiz-Reyes L, Lew CCH, Hasan MS, et al · · 2023 · cited 16× · PMID 36882644 · DOI 10.1186/s13613-023-01116-x
An update of the effects of vitamins D and C in critical illness.
Hill A, Starchl C, Dresen E, Stoppe C, et al · · 2022 · cited 12× · PMID 36726354 · DOI 10.3389/fmed.2022.1083760
[Vitamin C and D supplementation in critically ill patients].
Hill A, Starchl C, Dresen E, Stoppe C, et al · · 2023 · cited 5× · PMID 36629872 · DOI 10.1007/s00063-022-00986-6

Verify or expand the search:

Other trials of Ascorbic Acid

Trials testing the same drug.

NCT03066115 — Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation · Phase 1 · withdrawn
NCT04354428 — Treatment for COVID-19 in High-Risk Adult Outpatients · Phase 2, PHASE3 · terminated
NCT04342728 — Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation · NA · completed
NCT04328961 — Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) · Phase 2, PHASE3 · completed
NCT04035096 — The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients · Phase 1, PHASE2 · unknown

Other recruiting trials for Shock

Currently open trials in the same condition.

NCT07273643 — Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With · recruiting
NCT07009665 — Fluid Management and Individualized Resuscitation in Sepsis · NA · recruiting
NCT06713668 — Augmented Pacing for Shock in the Cardiac Intensive Care Unit · NA · recruiting
NCT06930235 — Effectiveness of Midodrine as an Adjuvant to Norepinephrine in Weaning Critically Ill Patients From Vasopressors · NA · recruiting
NCT06920173 — Pulse Study: Peripheral Use of Low-dose Vasopressors for Safety and Efficacy in the Intensive Care Unit · Phase 2 · recruiting

Other Clinical Evaluation Research Unit at Kingston General Hospital trials

Trials by the same sponsor.

NCT04242966 — The Effect of Higher Protein Dosing in Critically Ill Patients Ultrasound a Sub-study · Phase 3 · withdrawn
NCT04931940 — The EFFORT Trial and EFFORT Outcomes Sub-study (EFFORT-Outcomes) · NA · unknown
NCT05401552 — Phosphate Bioavailability Hormonal Response to a Breakfast Meal in Healthy Humans · NA · completed
NCT03160547 — The Effect of Higher Protein Dosing in Critically Ill Patients · NA · completed
NCT03021902 — Nutrition and Exercise in Critical Illness · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04138394 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinical Evaluation Research Unit at Kingston General Hospital
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04138394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing